Clinical Trials Browser

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05609903 2022-11-08

Anastase

Completed

52 enrolled

Breast

Breast Neoplasms

NCT02914470 2021-10-19

PROLOG

Phase 1 Completed

12 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02924883 2021-02-17

KATE2

Phase 2 Completed

202 enrolled 21 charts

Breast

Breast Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Phase 1 Completed

98 enrolled

Breast

Breast Neoplasms

Clinical Trials

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

AMBITION

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

MORPHEUS HR+BC

PROMETEO

Study to Evaluate CCS1477 in Advanced Tumours

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

IMpassion050

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

ALICE

ECLIPSE

ATRACTIB

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

AZTEC

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Anastase

PROLOG

KATE2

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer